ITRM20030596A1 - Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. - Google Patents

Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.

Info

Publication number
ITRM20030596A1
ITRM20030596A1 IT000596A ITRM20030596A ITRM20030596A1 IT RM20030596 A1 ITRM20030596 A1 IT RM20030596A1 IT 000596 A IT000596 A IT 000596A IT RM20030596 A ITRM20030596 A IT RM20030596A IT RM20030596 A1 ITRM20030596 A1 IT RM20030596A1
Authority
IT
Italy
Prior art keywords
ptx3
pentraxine
pathologies
reply
medication
Prior art date
Application number
IT000596A
Other languages
English (en)
Inventor
Barbara Bottazzi
Paolo Carminati
Cecilia Garlanda
Alberto Mantovani
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to IT000596A priority Critical patent/ITRM20030596A1/it
Priority to TW093137054A priority patent/TW200526246A/zh
Priority to KR1020067012245A priority patent/KR20070000415A/ko
Priority to CNA2004800371947A priority patent/CN1893975A/zh
Priority to EP04806879A priority patent/EP1706144A2/en
Priority to ARP040104816A priority patent/AR047159A1/es
Priority to CA002548452A priority patent/CA2548452A1/en
Priority to US10/584,292 priority patent/US20070098722A1/en
Priority to BRPI0418017-8A priority patent/BRPI0418017A/pt
Priority to AU2004305341A priority patent/AU2004305341A1/en
Priority to JP2006546487A priority patent/JP2007517021A/ja
Priority to MXPA06007080A priority patent/MXPA06007080A/es
Priority to PCT/IT2004/000714 priority patent/WO2005060997A2/en
Publication of ITRM20030596A1 publication Critical patent/ITRM20030596A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
IT000596A 2003-12-23 2003-12-23 Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3. ITRM20030596A1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IT000596A ITRM20030596A1 (it) 2003-12-23 2003-12-23 Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
TW093137054A TW200526246A (en) 2003-12-23 2004-12-01 Medicament comprising inhibitors of long pentraxin PTX3
KR1020067012245A KR20070000415A (ko) 2003-12-23 2004-12-21 긴 펜트락신 ｐｔｘ３의 억제제를 포함하는 약제
CNA2004800371947A CN1893975A (zh) 2003-12-23 2004-12-21 包含长正五聚蛋白ptx3抑制剂的药物
EP04806879A EP1706144A2 (en) 2003-12-23 2004-12-21 Medicament comprising inhibitors of long pentraxin ptx3
ARP040104816A AR047159A1 (es) 2003-12-23 2004-12-21 Medicamento que comprende inhibidores de pentraxina larga ptx3
CA002548452A CA2548452A1 (en) 2003-12-23 2004-12-21 Medicament comprising inhibitors of long pentraxin ptx3
US10/584,292 US20070098722A1 (en) 2003-12-23 2004-12-21 Medicament comprising inhibitors of long pentraxin ptx3
BRPI0418017-8A BRPI0418017A (pt) 2003-12-23 2004-12-21 medicamento compreendendo inibidores de pentraxina ptx3 longa
AU2004305341A AU2004305341A1 (en) 2003-12-23 2004-12-21 Medicament comprising inhibitors of long pentraxin PTX3
JP2006546487A JP2007517021A (ja) 2003-12-23 2004-12-21 長いペントラキシンｐｔｘ３の阻害剤を含む医薬
MXPA06007080A MXPA06007080A (es) 2003-12-23 2004-12-21 Medicamento que comprende inhibidores de pentraxina de cadena larga ptx3.
PCT/IT2004/000714 WO2005060997A2 (en) 2003-12-23 2004-12-21 Medicament comprising inhibitors of long pentraxin ptx3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000596A ITRM20030596A1 (it) 2003-12-23 2003-12-23 Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.

Publications (1)

Publication Number Publication Date
ITRM20030596A1 true ITRM20030596A1 (it) 2005-06-24

Family

ID=34708534

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000596A ITRM20030596A1 (it) 2003-12-23 2003-12-23 Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.

Country Status (13)

Country Link
US (1) US20070098722A1 (it)
EP (1) EP1706144A2 (it)
JP (1) JP2007517021A (it)
KR (1) KR20070000415A (it)
CN (1) CN1893975A (it)
AR (1) AR047159A1 (it)
AU (1) AU2004305341A1 (it)
BR (1) BRPI0418017A (it)
CA (1) CA2548452A1 (it)
IT (1) ITRM20030596A1 (it)
MX (1) MXPA06007080A (it)
TW (1) TW200526246A (it)
WO (1) WO2005060997A2 (it)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
EP2012816B1 (en) 2006-05-02 2012-06-27 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Use of thymosin 1, alone or in combination with ptx3 or ganciclovir, for the treatment of cytomegalovirus infection
WO2009075881A2 (en) * 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
KR101305515B1 (ko) * 2011-06-10 2013-09-06 경북대학교 산학협력단 펜트락신 3 단백질의 파킨슨 질환 진단 용도
EA030797B1 (ru) 2012-12-21 2018-09-28 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Система трансдермальной доставки гормонов (варианты) и способы ее применения
US20190226002A1 (en) * 2016-05-13 2019-07-25 The University Of Tokyo Obesity-related disease therapeutic agent by hepatic secretory metabolic regulator inhibitory action
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用
WO2019056991A1 (zh) * 2017-09-19 2019-03-28 臻崴生物科技有限公司 单克隆抗体或其抗原结合片段及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
IT1317927B1 (it) * 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
US20030195167A1 (en) * 2002-04-15 2003-10-16 Kowa Co., Ltd. PTX3-gene expression inhibitor

Also Published As

Publication number Publication date
BRPI0418017A (pt) 2007-04-17
EP1706144A2 (en) 2006-10-04
CA2548452A1 (en) 2005-07-07
TW200526246A (en) 2005-08-16
US20070098722A1 (en) 2007-05-03
AR047159A1 (es) 2006-01-11
WO2005060997A2 (en) 2005-07-07
JP2007517021A (ja) 2007-06-28
MXPA06007080A (es) 2006-09-04
CN1893975A (zh) 2007-01-10
AU2004305341A1 (en) 2005-07-07
KR20070000415A (ko) 2007-01-02
WO2005060997A3 (en) 2005-09-09

Similar Documents

Publication Publication Date Title
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DE50212546D1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
IS7663A (is) Starfrænar hjartavöðvafrumur úr mannafósturstofnfrumum
ITTO20040621A1 (it) Immunogeno sintetico per la terapia e profilassi dell'abuso di droghe e sostanze psicoattive
ITMI20030025A1 (it) Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
ITRM20030596A1 (it) Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
CL2004000652A1 (es) Uso de lactulosa para la inhibicion de infecciones por rotavirus de celulas animales o humanas.
ITMI20020773A0 (it) Farmaci per il trattamento dell'artrite
AR043327A1 (es) Uso de inhibidores de quinurenina 3- hidroxilasa para el tratamiento de la diabetes
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
CY1105105T1 (el) Χρηση του διστροντιου αλατος του 2-[ν,ν-δι(καρβοξυμεξυλ) amino]- 3-κυανο-4-καρβοξυμεθυλ-θειοφενο-5-καρβοξυλικου οξεος για τη ληψη φαρμακων που προοριζονται για τη θεραπεια γαστρο-δωδεκαδακτυλικων πονων
ITRM20000341A0 (it) Composti utili per la preparazione di medicamenti ad attivita' inibitrice della fosfodiesterasi iv.
EA200500958A1 (ru) Дейтерированные производные катехоламина, а также лекарственные средства, содержащие эти соединения
BRPI0409790A (pt) 7-azaindóis e seu uso como terapêuticos
AU2003272189A1 (en) Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
ITRM20040607A1 (it) Analoghi della dermorfina ad attivita' analgesica.
ITRM20030178A1 (it) Uso della l-carnitina per il trattamento di patologie cardiovascolari.
ITMI20030972A1 (it) Indazolo dotato di attivita' analgesica, metodo per prepararlo e composizione farmaceutica che lo comprende.
ITMI20021771A1 (it) Uso di soluzioni attive per la disinfezione e/o sterilizzazione di un riunito dentale e relativo metodo.
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
ITRM20000106A0 (it) Composizione per la prevenzione e/o il trattamento di vascolopatie, che comprende propionil l-carnitina e coenzima q10.
ITUD20030196A1 (it) Procedimento per la preparazione di dosaggi farmaceutici contenenti molteplici principi attivi.
ITRM20010293A1 (it) Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore.